Gargling salt water is a time-tested way to alleviate sore-throat pain. As a nasal lavage, it can help clear stuffy sinuses associated with colds and allergies. But, is it effective against the symptoms of COVID-19?

The U.S. Food and Drug Administration (FDA) issued Heron Therapeutics a Complete Response Letter (CRL) for its New Drug Application (NDA) for HTX-011 for the management of postoperative pain.

Specifically, the report indicated that biotechnology companies drove the healthcare industry to make up almost two-thirds of IPO activity in the second quarter of 2020.

Clinical-stage biotechnology company BioNTech announced a private investment of $250 million today, led by Temasek and other investors.

San Francisco-based Audentes Therapeutics reported two deaths in its gene therapy clinical trial. The therapy, AT132, is for X-linked myotubular myopathy.

DBV Technologies, located just outside Paris, announced it is cutting jobs while it awaits news from the U.S. Food and Drug Administration (FDA) about its application for Viaskin Peanut.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.

It was a busy week for clinical trial updates. Here’s a look.

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.

This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

With Moderna on the precipice of launching its Phase III trial of 30,000 people for its COVID-19 vaccine, mRNA-1273, it is ramping up manufacturing capabilities.

One month after Vaxart announced the selection of its lead vaccine candidate for COVID-19, the Bay Area-based company said it has been selected to participate in the U.S. government’s Operation Warp Speed program.

Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.

Despite the bleak challenges brought on by COVID-19, Bill Sibold, executive vice president of Sanofi Genzyme, is optimistic that some of the greatest discoveries in medicine and treating various diseases are within the grasp of the pharmaceutical industry.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

The lung model in Draper’s new organ-on-a-chip platform, PREDICT96, replicates the structure and function of human lung tissue from donors with multiple patient profiles on a 96-well plate, increasing assay throughput by 10-fold.

The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.

Shares of Zogenix were up more than 16% in premarket trading following the regulatory approval of the epilepsy drug Fintepla for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy, in patients ages two and above.

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system.

A team from Lawson Health Research Institute and Western University are the first in the world to profile the body's immune response to COVID-19. By studying blood samples from critically ill patients at London Health Sciences Centre (LHSC), the research team identified a unique pattern of six molecules that could be used as therapeutic targets to treat the virus. The study is published this week in Critical Care Explorations.